Editorial dispatches, monthly.

Introduction

Spinal muscular atrophy (SMA) has undergone one of the most dramatic transformations in modern medicine. Once considered a leading genetic cause of infant mortality, SMA is now at the forefront of precision therapeutics, driven by advances in gene therapy and RNA-targeted interventions. This shift has not only altered clinical outcomes but has also redefined expectations for rare disease treatment.

Disease mechanism and genetic basis

SMA is caused by mutations or deletions in the SMN1 gene, resulting in insufficient production of survival motor neuron (SMN) protein. This deficiency leads to progressive degeneration of motor neurons in the spinal cord, ultimately impairing voluntary muscle movement.

Humans possess a paralog gene, SMN2, which produces limited functional SMN protein due to alternative splicing. The number of SMN2 copies partially influences disease severity, providing a therapeutic target for intervention.

Therapeutic breakthroughs

Recent years have seen the emergence of disease-modifying therapies that directly target the underlying genetic defect:

• Gene replacement therapy delivers a functional copy of SMN1 via viral vectors, offering long-term benefit from a single administration.
• Splicing modifiers enhance the inclusion of exon 7 in SMN2 transcripts, increasing production of functional SMN protein.

These approaches have demonstrated unprecedented clinical benefits, including improved survival, attainment of motor milestones, and reduced need for ventilatory support.

Importance of early intervention

Clinical evidence consistently highlights the critical importance of early treatment. Presymptomatic infants identified through newborn screening programmes exhibit significantly better outcomes than those treated after symptom onset.

This has led to widespread implementation of newborn screening for SMA, enabling early diagnosis and timely intervention. The paradigm has shifted from reactive treatment to proactive disease management.

Real-world evidence and long-term outcomes

While clinical trials have established efficacy, real-world data are essential to understand long-term outcomes. Patient registries and observational studies are providing valuable insights into:

• Durability of therapeutic effects
• Long-term safety profiles
• Functional outcomes over time

Questions remain regarding whether early gains can be sustained into adolescence and adulthood.

Challenges and unresolved questions

• Durability of gene therapy. Tissue growth, vector persistence, and immune responses may all influence long-term efficacy of a so-called one-time treatment.
• Treatment sequencing. With multiple options available, the optimal sequence or combination strategy is still being defined.
• Access and cost. High therapy prices create significant barriers, particularly in low- and middle-income countries.

The role of medical communications

As the SMA landscape evolves, translating complex clinical data into clear, actionable insight is essential for clinicians making treatment decisions, regulators evaluating therapies, and patients and caregivers weighing options. Effective communication is what turns scientific advances into real-world impact.

Future directions

The next phase of SMA research is focused on redosing strategies for gene therapy, next-generation vectors, and biomarkers to monitor treatment response — all aimed at refining therapy and improving long-term outcomes.

Conclusion

SMA has transitioned from a fatal paediatric condition to a manageable disease with transformative therapeutic options. While challenges remain, the progress achieved underscores the potential of precision medicine to reshape the future of rare disease treatment.

Introduction

Sickle cell disease (SCD) has long been a paradigm of unmet medical need, characterised by chronic pain, organ damage, and reduced life expectancy. Recent advances in gene editing — particularly CRISPR-based approaches — have introduced the possibility of a functional cure.

Pathophysiology

SCD is caused by a single nucleotide mutation in the β-globin gene, producing abnormal haemoglobin (HbS). Under low oxygen conditions, HbS polymerises and red blood cells adopt a sickle shape, leading to:

• Vaso-occlusion
• Chronic haemolysis
• Inflammation and organ damage

Evolution of treatment

Traditional management has focused on symptom control and prevention of complications, including hydroxyurea therapy, blood transfusions, and supportive care. While effective in reducing morbidity, these approaches do not address the underlying genetic defect.

Gene therapy and gene editing

Recent developments have transformed the treatment landscape:

• Gene addition therapies introduce functional copies of the β-globin gene.
• Gene editing approaches modify haematopoietic stem cells to increase fetal haemoglobin production.

CRISPR-based therapies have demonstrated promising results in early clinical trials, with patients achieving sustained increases in haemoglobin and reduced vaso-occlusive events.

Clinical and ethical considerations

• Long-term safety. Gene editing is relatively new; off-target effects and unintended genetic changes remain key concerns.
• Accessibility. Therapies are complex and costly, requiring specialised infrastructure that limits equitable access.
• Ethical implications. Editing the human genome raises lasting questions about long-term consequences and societal impact.

Real-world implementation challenges

Scaling gene therapies from clinical trials to routine practice involves overcoming logistical barriers, including manufacturing capacity, patient eligibility criteria, and healthcare system readiness.

Future outlook

Ongoing research aims to improve safety and efficiency of gene editing, develop less invasive delivery methods, and expand access to broader patient populations.

Conclusion

SCD is entering a new era of treatment, with gene editing offering unprecedented potential. Translating that promise into widespread clinical benefit will require addressing significant scientific, logistical, and ethical challenges in parallel.

Introduction

Amyotrophic lateral sclerosis (ALS) remains one of the most devastating neurodegenerative diseases, characterised by progressive loss of motor neurons and eventual respiratory failure. Despite decades of research, therapeutic progress has been incremental.

Disease biology

ALS involves degeneration of upper and lower motor neurons, leading to muscle weakness, paralysis, and death. The disease is heterogeneous, with both genetic and sporadic forms. Key mechanisms include:

• Protein aggregation
• Oxidative stress
• Neuroinflammation

Current treatment landscape

Approved therapies provide modest benefits, primarily slowing disease progression rather than reversing it. The need for more effective treatments remains urgent.

Emerging therapeutic approaches

RNA-based therapies. By targeting specific genetic mutations, RNA therapies aim to reduce production of toxic proteins, marking a shift toward personalised medicine.

Biomarker development. Identifying reliable biomarkers is critical for early diagnosis and for monitoring treatment response.

Clinical trial challenges

ALS trials face unique challenges that complicate design and interpretation:

• Small patient populations
• Rapid disease progression
• Heterogeneity in disease presentation

Role of real-world evidence

Real-world data are increasingly used to complement clinical trials, providing insight into disease progression and long-term treatment outcomes that controlled studies alone cannot capture.

Future directions

Research efforts are focused on combination therapies, earlier intervention strategies, and improved trial designs that better match the realities of ALS biology.

Conclusion

While progress in ALS has been slower than in other rare diseases, ongoing research offers hope. Continued innovation and collaboration will be essential to achieve meaningful breakthroughs for patients and families.